MunichHigher doses produced bigger drops in inflammation markers.
It’s unproven whether lower inflammation markers will mean fewer heart attacks.
A 2017 trial proved inflammation drives heart disease, but its drug raised fatal infection risk.
Novartis has not said whether it will fund a trial testing heart outcomes.
Sources: STAT